COMPANY PROFILE

Sanmai Technologies

A neurotechnology platform for non-invasive ultrasound neurotherapeutics, using AI to address mental health and neurological disorders

Sunnyvale, United StatesFounded 2020Health Tech & Medtech

Valuation $50–100M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Sanmai Technologies

Sanmai Technologies, a public benefit corporation, was founded by Jay Sanguinetti. Sanguinetti has a background in philosophy, neuroscience, and cognitive psychology, specializing in psychophysiological measures like EEG and fMRI.

Sanmai is a neurotechnology company that has developed a platform for non-invasive ultrasound neurotherapeutics to address mental health and neurological disorders. The company is currently in stealth mode and has created a device that combines artificial intelligence with ultrasound technology to scan the brain. This technology is designed to be a non-invasive alternative for treating these conditions. Sanmai is already conducting clinical trials for their device.

The company recently secured $12 million in a Series A funding round. The round was led by Reid Hoffman, the co-founder of LinkedIn, who has also joined the company's board.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Sunnyvale, United States
Employees: 10
Open positions: 3
Dealroom signal: 66.3/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Mental Health, Brain Computer Interfaces, DT and LS, science-based
Technology: Deep Tech
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jul 2025	$12M	$48M	Reid Hoffman	↗
SUPPORT PROGRAM✓Other financing	Feb 2025	$0	—	One Mind Accelerator	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Sanmai Technologies website traffic

Latest recorded traffic for Sanmai Technologies is 1K monthly website visits, down 28.6% over the last three months.

Latest monthly visits1K 3-month web change-28.6%

Monthly website visitsJul 2025–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Part time Project ManagerSunnyvale, CA · Project Management · Jul 19, 2026 Software EngineerSunnyvale, CA · Backend Development · Jul 16, 2026 Contract Technical WriterSunnyvale, CA · Other · Jul 16, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XTXi'an Dome Medical TechnologyNon-invasive deep brain neuromodulation for neurological disorders	China	Operational	—	$17M	$55M
BRBrightmindAI-powered, at-home neuromodulation device for migraine therapy	Vienna, Austria	Operational
NENextsenseDevelops in-ear neuro-sensing wearables and a data platform to revolutionize brain health, disease management, and drug discovery	Mountain View, United States	Operational
NŪNūrioUnlocking a new type of mobility accessibility and health	Minneapolis, United States	Operational
RNRestorative NeurotechnologiesProducing wearable medical device in order to enhance the strength of the rehabilitation for cognitive disease or enhance sport performance	Palermo, Italy	Operational
CECereGateBrain-Machine Interface company establishing new ways of communication	Munich, Germany	Operational
BRBrainpatchBrainPatch is a neurotech startup pioneering accessible, personalized non-invasive brain stimulation	London, United Kingdom	Operational
BIBIOSBIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals	Cambridge, United Kingdom	Operational